Clinical Trials Sponsored by Ethos Research & Development

Total 5619 results

Janssen Research & Development, LLC

Completed

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (VOYAGE 2)

Psoriasis

United States, Australia, Poland, Germany, Spain, Korea, Republic of, Canada, Russian Federation, Czechia
Janssen Research & Development, LLC

Terminated

A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)

Metastatic Colorectal Cancer

United States, Spain, Australia, Belgium, Israel, Austria, Czechia, United Kingdom, Hungary, Italy, Netherlands, Poland, Switzerland
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Metastatic Non-Small Cell Lung Cancer
Janssen Research & Development, LLC

Completed

A Study Exploring the Use of Challenge Agents in Healthy Volunteers - Intervention Specific Appendix

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants

Healthy

Netherlands
Janssen Research & Development, LLC

No longer available

Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use

Healthy
Janssen Research & Development, LLC

Completed

A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer

Advanced Colorectal Cancer | Symptomatic Colorectal Cancer | Colorectal Cancer With Cachexia

Poland
Janssen Research & Development, LLC

Completed

Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.

Patients Undergoing Repeat Peripheral Artery Revascularization

United States
Janssen Research & Development, LLC

Completed

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

Psoriasis

United States
Janssen Research & Development, LLC

Completed

Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants

Healthy Participants

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Russian Federation, Austria, Hungary, ... and more
Janssen Research & Development, LLC

Completed

A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

Prostatic Neoplasms

United States, Canada
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy (PRELUDE)

Macular Degeneration | Geographic Atrophy | Visual Acuity

United States
Janssen Research & Development, LLC

Completed

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression (SUSTAIN-2)

Treatment-resistant Depression

United States, Australia, France, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Poland, Bulgaria, Malaysia, South Africa, Turkey, Finland, Korea, Republic of, Brazil, Austria, Sweden, Lithuania
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (TRANSFORM-1)

Treatment-resistant Depression

United States, France, Belgium, Mexico, Canada, Brazil, Estonia, Hungary, Slovakia
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

Influenza A Virus

United States, France, Belgium, Germany, Hong Kong, Spain, Malaysia, Turkey, Canada, Netherlands, Singapore, Brazil, New Zealand, Australia, Sweden
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-53718678 Administered as Oral Concept Formulation Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of Oral Concept Formulation

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)

Healthy

United States
Janssen Research & Development, LLC

Completed

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China, Taiwan, Korea, Republic of
Janssen Research & Development, LLC

Completed

A Study of New Transdermal Contraceptive Patch at End of Shelf Life and Currently Marketed EVRA at the Beginning of Shelf Life in Healthy Women

Healthy

Netherlands, Germany, Belgium
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)

Depressive Disorder, Treatment-Resistant
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Obesity

United States, Belgium, United Kingdom, Sweden, Poland, Canada
Janssen Research & Development, LLC

Completed

A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study in Healthy Volunteers to Assess the Effect of Different Types of Food on a Single-dose of JNJ-64417184 Administered as Tablets

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan

Attention Deficit Disorder With Hyperactivity

United States
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung

Adenocarcinoma of Lung

Spain, Belgium, United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery (TEXT-TKR)

VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery

Belgium, Italy, Malaysia, Latvia, Spain, Turkey, Bulgaria, United States, Lithuania, Russian Federation, Ukraine, Japan, Argentina, Brazil, Canada, Poland
Janssen Research & Development, LLC

Completed

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

Attention Deficit Disorder With Hyperactivity

United States
Janssen Research & Development, LLC

Completed

Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)

Alzheimer Disease

France, Belgium, Germany, Spain, Sweden
Janssen Research & Development, LLC

Completed

A Study to Assess the Drug-Drug Interaction Between Bedaquiline and Clarithromycin in Healthy Adult Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United Kingdom, United States, Belgium, Germany, Romania, Canada, Netherlands, Russian Federation, Poland, Hungary, Czechia
Janssen Research & Development, LLC

Completed

A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States
Janssen Research & Development, LLC

Terminated

A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

France, United Kingdom, Spain, Belgium, Netherlands, Germany, Denmark
Janssen Research & Development, LLC

Completed

An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

Depressive Disorder, Major

United States, Poland, United Kingdom, Russian Federation, Canada
Janssen Research & Development, LLC

Completed

Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

HIV-1

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Postmenopausal | Metastatic ER+ Her2- Breast Cancer

United States, France, Ukraine, United Kingdom, Belgium, Spain, Netherlands, Korea, Republic of, Russian Federation, Poland, Luxembourg, Ireland
Janssen Research & Development, LLC

Completed

Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Fluoroquinolone Associated Disability

Sinusitis | Urinary Tract Infections | Bronchitis

United States
Janssen Research & Development, LLC

Completed

A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

United States, Australia, France, Ukraine, Germany, Israel, Poland, Bulgaria, Romania, Russian Federation, Canada, Netherlands, Belgium, Hungary
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants

Healthy

Japan, United Kingdom
Janssen Research & Development, LLC

Completed

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Cardiovascular Diseases | Diabetes Mellitus, Type 2

United States

3

Subscribe